Clinical Trial

SEMA4C as a Relapse Biomarker in Breast Cancer

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated October 7, 2021 (before its estimated August 1, 2023 completion). Its status may not reflect the trial's current state.
Summary
Breast cancer remains the most common cancer in women worldwide. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The objective of this study is to investigate SEMA4C's potential role as an early relapse biomarker in breast cancer.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT03663153
Lead Sponsor Tongji Hospital
Collaborators: Hubei Cancer Hospital, Qilu Hospital of Shandong University, Wuhan Central Hospital, Xiangyang Central Hospital, The First People's Hospital of Jingzhou, The First Affiliated Hospital with Nanjing Medical University
Conditions Breast Cancer
Enrollment 4,200 participants
Start Date 2022-09-01
Primary Completion 2023-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2021-10-07